Aramco and Yokogawa Achieve a Major Milestone with Commissioning of Multiple Autonomous Control AI Agents at Major Gas Facility
29.10.2025 03:00:00 CET | Business Wire | Press Release
Yokogawa Electric Corporation (TOKYO: 6841, “Yokogawa”), a leader in process automation technology, announces it has achieved a historic milestone in the deployment of industrial artificial intelligence (AI) solutions with Aramco, one of the world’s leading integrated energy and chemicals companies. Multiple autonomous control AI*1 agents have been successfully implemented by Yokogawa at Aramco’s Fadhili Gas Plant in the Kingdom of Saudi Arabia to enhance operational efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028792329/en/
Fadhili Gas Plant (Courtesy of Aramco)
The AI solution developed by Yokogawa uses multiple, coordinated AI agents of the Factorial Kernel Dynamic Policy Programming (FKDPP)*2 reinforcement learning-based AI algorithm to directly and autonomously control and optimize acid gas removal (AGR) operations at the Fadhili Gas Plant.
The solution was introduced in three phases, progressively optimizing various sections until autonomous control of the core process in the AGR unit was achieved. To ensure safety, Yokogawa first created a simulator of the plant to train AI agents, and then evaluated their reliability and validity. Subsequently, they were integrated with Yokogawa's CENTUM VP integrated production control system to leverage the safety functions of the existing plant.
Implementation is currently undergoing a detailed evaluation, but initial results from Fadhili Gas Plant demonstrate a 10% to 15% reduction in its amine and steam usage, around 5% reduction in power usage, improved process stability, and a significant decrease in operator manual intervention, despite ambient condition changes.
Aramco Engineering Services Senior Vice President, Khalid Y. Al Qahtani, said: “Aramco has embarked on an ambitious plan to unlock value by deploying a wide range of industrial AI applications across our operations. The collaboration with Yokogawa is one of many initiatives that focus on improving efficiency, enhancing sustainability, and generating more value for our shareholders. It reflects how the company is harnessing advanced technology, including AI, to elevate its performance and reinforce its position as a technology leader in the energy sector. We look forward to building on this important milestone, as we explore further adoption of cutting-edge solutions that will contribute to a new era of industrial innovation.”
Kunimasa Shigeno, Director, President & CEO, and Representative Executive Officer of Yokogawa Electric, said: “We are honored that Yokogawa was entrusted by Aramco to implement such ground-breaking technology in one of its major facilities. We are very pleased that the results have already exceeded expectations. Yokogawa is advocating the transition from industrial automation to industrial autonomy (IA2IA), and this deployment proves that we are ready to lead the way towards safe and secure autonomous operations for plants in the energy sector.”
*1 | Yokogawa defines autonomous control AI as AI that deduces the optimum method for control independently and has a high level of robustness enabling it to autonomously handle, to a certain extent, situations that it has not previously encountered. |
*2 | A reinforcement learning AI algorithm jointly developed by Yokogawa Electric and the Nara Institute of Science and Technology (NAIST). FKDPP received the Prime Minister's Prize at the 2023 Japan Industrial Technology Awards (Nihon Sangyo Gijyutsu Taisho). |
About Aramco
As one of the world’s leading integrated energy and chemicals companies, our global team is dedicated to creating impact in all that we do, from providing crucial oil supplies to developing new energy technologies. We focus on making our resources more dependable, more sustainable and more useful, helping to promote growth and productivity around the world. https://www.aramco.com/
About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,000+ employees in a global network of 128 companies spanning 62 countries.
For more information, visit www.yokogawa.com.
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Aramco, Yokogawa Electric Corporation or their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251028792329/en/
Contacts
Media enquiries
Yokogawa Electric Corporation
Public Relations Department, Integrated Communications Center
Tokyo, Japan
Yokogawa-pr@cs.jp.yokogawa.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom